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ing any positive result concerning new anticalcification
techniques in vascular bioprostheses.
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Reply to the Editor:
The comments by Dr. Goto were difficult for us to
understand. He noted that there was mild-to-moderate
calcification of glutaraldehyde-treated porcine aortic
cusps implanted in the pulmonary circulation of dogs,
whereas no calcific changes were observed in glutaralde-
hyde-treated valved conduits in the systemic circulation of
dogs. However, he provides no detailed explanation of
what this means. He also noted that the dog is not
generally considered to be a useful model for the study of
accelerated calcification. This sentence was quoted di-
rectly from the original article of Dr. Shemin.1 The point
of our article was the evaluation of a trileaflet biopros-
thetic valve both hemodynamically and pathologically.
Goto’s comments on this matter are also quoted in other
articles, as follows2, 3: The point of Dr. Shemin’s article
was the evaluation of a unileaflet pericardial bioprosthetic
valve both hemodynamically and pathologically in sheep
and was not for evaluation of calcification in the dog. Dr.
Shemin considered that the dog was not a useful model
for calcification according to previous investigations2, 3
that demonstrated no significant calcification despite 2
years of valve function in dogs.
We used dogs to evaluate our new conduit hemodynam-
ically and pathologically. The aim of our study was not the
evaluation of calcification. If Dr. Goto is interested in the
anticalcification effect of our bioprosthesis, we suggest he
may want to study our conduit in sheep. The details of the
graft processing are noted in “Materials and methods”
and “Discussion” of our article. References4, 5 are added
for additional clarification.
Dr. Goto explained the calcification of the polyepoxy
compound–treated aorta based on his colleague’s per-
sonal data. However, since this is not published informa-
tion, we would need more information to respond more
specifically. The laboratory data, including the number of
animals, name and concentration of the polyepoxy com-
pound, and the catalyst, reaction velocity, reaction time,
temperature, change of the pH during cross-linking, col-
lagen content of the aortic wall, cross-linking ratio of the
collagen, and the pK of the material in wet condition
would be necessary before we could comment.
Yukio Ichikawa, MD, PhD
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Early failure of freehand aortic stentless xenograft
valves
To the Editor:
Luciani, Bertolini, and Mazzucco1 report two cases of
supposed early (,12 months) failure with the O’Brien-
Angell stentless porcine xenograft aortic valve (now the
CryoLife-O’Brien model 300 composite aortic stentless
xenograft; CryoLife, Inc., Marietta, Ga.), which they
label as structural failures. The first patient required
reoperation for aortic valve replacement at 8 months. A
large periprosthetic dehiscence of the valve from the
host “for a length of about 1 cm at the level of the
native noncoronary cusp” had occurred. The authors
published a photograph of the explanted valve, which
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